Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
IGF-1 LR3 vs Lonapegsomatropin (Skytrofa)
An educational, source-based comparison of IGF-1 LR3 and Lonapegsomatropin (Skytrofa) — how each peptide works, what it's researched for, and what to know before going deeper.
A modified form of insulin-like growth factor-1 with an Arg3 substitution and N-terminal extension that reduces binding to IGFBPs, dramatically extending its half-life and free fraction in circulation.
- Muscle protein synthesis (preclinical)
- Tissue repair signaling
- Cell-culture growth applications
- • Hypoglycemia risk via insulin-receptor cross-activity.
- • Not FDA-approved for human therapeutic use; banned by WADA.
Prodrug of somatropin with a transient PEG linker that releases unmodified GH over ~1 week, providing once-weekly dosing for pediatric GH deficiency.
- Pediatric growth hormone deficiency
- • FDA-approved.
- • Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
IGF-1 LR3 vs Lonapegsomatropin (Skytrofa) — Key differences
- Class: IGF-1 LR3 is classified as Growth Factor, while Lonapegsomatropin (Skytrofa) is GH Analog · Endocrine.
- Primary research focus: IGF-1 LR3 — muscle protein synthesis (preclinical); Lonapegsomatropin (Skytrofa) — pediatric growth hormone deficiency.
- Tag: Growth · Recovery vs FDA-Approved · Endocrine.